Other drugs that inhibit HMGB1 levels and hence inhibit BLM-induced lung fibrosis include thrombomodulin, fatty acid, nitrogenes, astragaloside IV, Yupingfeng, pulmonary rehabilitation mixture, dioscin, simvastatin, and some fragments of the depolymerized heparins (Cui et al. 2015; Kida et al. 2018; Li et al. 2017; Liu et al. 2014; Wilkinson et al. 2020; Wu and Wang 2019; Yan et al. 2017; Zhang et al. 2015b). The gene discussed is HMGB1; the disease is pulmonary fibrosis.